Giancarlo Castaman
University of Florence
435 Papers
3.6K Citations
Giancarlo Castaman is an academic researcher from University of Florence. The author has contributed to research in topics: Medicine & Von Willebrand disease. The author has an hindex of 60, co-authored 389 publications. Previous affiliations of Giancarlo Castaman include UniFi & University of Milan.
Chat about Author
Papers
Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect.
Ilaria Guella,Giulia Soldà,Silvia Spena,Rosanna Asselta,Rossella Ghiotto,Maria Luisa Tenchini,Giancarlo Castaman,Stefano Duga +7 more
TL;DR: The functional consequences of two splicing mutations leading to FXI deficiency have been elucidated and a novel missense mutation in the FIX-binding region of the FXI A3 domain leading to a CRM+ deficiency is reported.
26
ABO blood group also influences the von willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854Gln, and the missense mutation Cys2362Phe
TL;DR: The levels of von Willebrand factor (VWF) in plasma are influenced by several variables, such as age, blood group, pregnancy, hormones, and smoking.
25
Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients
Giancarlo Castaman,F. Rodeghiero,Antonella Lattuada,Giuseppe La Greca,Pier Mannuccio Mannucci +4 more
TL;DR: This study does not confirm the presence of a structural defect of plasma vWF and the reduction of platelet vWF content in uremia, and its multimeric pattern was indistinguishable from that of normal platelets.
25
Management of thrombocytopenia in cancer.
Giancarlo Castaman,Lisa Pieri +1 more
TL;DR: Platelet transfusion remains the cornerstone of treatment, but its use should always be weighted taking into consideration the actual risk of bleeding to avoid inappropriate use and wasting of resources.
25
Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency
Manuel Carcao,Carmen Altisent,Giancarlo Castaman,Katsuyuki Fukutake,Bryce A. Kerlin,Craig M. Kessler,Riitta Lassila,Diane J. Nugent,Johannes Oldenburg,May-Lill Garly,Anders Rosholm,Aida Inbal +11 more
TL;DR: RFXIII-A 2 prophylaxis provided sufficient haemostatic coverage for 12 minor surgeries without the need for additional FXIII therapy; eight procedures were performed within 7 days of the patient's last scheduled rFXIII -A 2 dose, and four were performed 10 to 21 days after the last dose.